Publication:
Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin

dc.contributor.authorPhillips, Patricia G.
dc.contributor.authorCui, Huadong
dc.contributor.authorAbdel, Hani Nabi
dc.contributor.authorSajjad, Munawwar
dc.contributor.authorBernacki, Ralph
dc.contributor.authorVeith, Jean
dc.contributor.authorMousa, Shaker A.
dc.contributor.buuauthorYalçın, Murat
dc.contributor.departmentVeterinerlik Fakültesi
dc.contributor.departmentFizyoloji Ana Bilim Dalı
dc.contributor.orcid0000-0002-5600-8162
dc.contributor.researcheridAAG-6956-2021
dc.contributor.scopusid57192959734
dc.date.accessioned2021-12-14T08:28:54Z
dc.date.available2021-12-14T08:28:54Z
dc.date.issued2011-02
dc.description.abstractBackground: Recent prospective clinical trials of low molecular weight heparins (LMWHs) have demonstrated that these agents may provide significant advantages in terms of progression-free and overall survival in certain subgroups of cancer patients. The mechanisms of improved survival associated with LMWHs are not known, and may involve direct and/or indirect effects on tumor growth. The purpose of this study was to investigate the effects of LMWH and a sulfated non-anticoagulant LMWH (S-NACH) on tumor chemotherapeutic uptake and chemoresponse. Materials and Methods: LMWH and S-NACH were tested for their ability to reduce tumor growth and tumor-associated angiogenesis using three different in vivo models. Biodistribution studies were undertaken to determine the effect of these agents on uptake of paclitaxel (PACL) and doxorubicin (Dox) by breast cancer tumor xenografts. Results: LMWH and S-NACH (10 mg/kg s.c. daily) effectively limited tumor growth of human A549 lung adenocarcinoma xenografts in the nude mouse. In an MDA453/LCC6 breast tumor xenograft model, PACL plus S-NACH showed significant (p<0.01) tumor growth suppression and improved survival when compared to PACL alone. LMWH increased [I124-]-PACL uptake into MDA453/LCC6 tumors, with tumor:muscle ratios several fold greater than that of [I124-]-PACL alone 24 h post-injection. Similarly, LMWH and S-NACH significantly (p<0.01) increased the uptake of Dox by 1.5-2 fold in MCF7 Dox-resistant tumor xenografts. Conclusion: Protocols utilizing adjuvant or neoadjuvant therapy with LMWH or S-NACH could lead to increased tumor chemo responsiveness, potentially overcoming tumor chemoresistance.
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA (CA121636)
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI) (R43CA121636)
dc.identifier.citationPhillips, P. G. vd. (2011). "Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin". Anticancer Research, 31(2), 411-419.
dc.identifier.endpage419
dc.identifier.issn0250-7005
dc.identifier.issn1791-7530
dc.identifier.issue2
dc.identifier.pubmed21378319
dc.identifier.scopus2-s2.0-79953246591
dc.identifier.startpage411
dc.identifier.urihttp://hdl.handle.net/11452/23238
dc.identifier.volume31
dc.identifier.wos000288684800005
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherInt Inst Anticancer Research
dc.relation.collaborationSanayi
dc.relation.collaborationYurt dışı
dc.relation.journalAnticancer Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOncology
dc.subjectNon-anticoagulant heparins
dc.subjectChemotherapy
dc.subjectHeparins
dc.subjectTissue factor
dc.subjectCancer
dc.subjectSurvival
dc.subjectInhibition
dc.subjectTherapy
dc.subjectAngiogenesis
dc.subjectMetastasis
dc.subjectTinzaparin
dc.subjectMechanisms
dc.subjectResistance
dc.subject.emtreeDoxorubicin
dc.subject.emtreeLow molecular weight heparin
dc.subject.emtreePaclitaxel
dc.subject.emtreeSulfated non anticoagulant low molecular weight heparin
dc.subject.emtreeTinzaparin
dc.subject.emtreeAnimal experiment
dc.subject.emtreeAnimal model
dc.subject.emtreeAnimal tissue
dc.subject.emtreeAntiangiogenic activity
dc.subject.emtreeAntineoplastic activity
dc.subject.emtreeArticle
dc.subject.emtreeBreast cancer
dc.subject.emtreeCancer inhibition
dc.subject.emtreeCancer resistance
dc.subject.emtreeControlled study
dc.subject.emtreeDrug distribution
dc.subject.emtreeDrug effect
dc.subject.emtreeDrug efficacy
dc.subject.emtreeDrug potentiation
dc.subject.emtreeDrug uptake
dc.subject.emtreeEmbryo
dc.subject.emtreeFemale
dc.subject.emtreeHuman
dc.subject.emtreeHuman cell
dc.subject.emtreeIn vivo study
dc.subject.emtreeLung adenocarcinoma
dc.subject.emtreeMouse
dc.subject.emtreeNonhuman
dc.subject.emtreePriority journal
dc.subject.emtreeTreatment response
dc.subject.emtreeTumor xenograft
dc.subject.emtreeUnclassified drug
dc.subject.meshAdenocarcinoma
dc.subject.meshAnimals
dc.subject.meshAntibiotics, antineoplastic
dc.subject.meshAnticoagulants
dc.subject.meshAntineoplastic agents, phytogenic
dc.subject.meshBreast neoplasms
dc.subject.meshCell line, tumor
dc.subject.meshChick embryo
dc.subject.meshDoxorubicin
dc.subject.meshDrug interactions
dc.subject.meshDrug resistance, neoplasm
dc.subject.meshFemale
dc.subject.meshHeparin, low-molecular-weight
dc.subject.meshHumans
dc.subject.meshLodine radioisotopes
dc.subject.meshLung neoplasms
dc.subject.meshMice
dc.subject.meshMice, nude
dc.subject.meshPaclitaxel
dc.subject.meshTissue distribution
dc.subject.meshXenograft model antitumor assays
dc.subject.scopusVenous Thromboembolism; Low Molecular Weight Heparin; Anticoagulant Agent
dc.subject.wosOncology
dc.titleIncreased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin
dc.typeArticle
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentVeterinerlik Fakültesi/Fizyoloji Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: